Novartis Ag (NVSEF) Change in Taxes (2020 - 2026)

Novartis Ag has disclosed Change in Taxes across 7 years of filings, most recently posting -$683.0 million for Q1 2026.

• Change in Taxes for Q1 2026 came in at -$683.0 million, up 14.41% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.3 billion (down 10.3% YoY), and the FY2025 annual result was -$814.0 million, changed N/A from the prior year.
• Change in Taxes came in at -$683.0 million for Q1 2026 at Novartis Ag, up from -$814.0 million in the prior quarter.
• In the past five years, Change in Taxes ranged from a high of $261.0 million in Q4 2023 to a low of -$814.0 million in Q4 2025.
• The 5-year median for Change in Taxes is -$403.0 million (2023), against an average of -$389.9 million.
• Across the five-year window, Change in Taxes jumped 202.76% in 2023 and tumbled 412.82% in 2024, its largest moves.
• Novartis Ag's Change in Taxes stood at -$254.0 million in 2022, then surged by 202.76% to $261.0 million in 2023, then slumped by 278.16% to -$465.0 million in 2024, then plunged by 75.05% to -$814.0 million in 2025, then increased by 16.09% to -$683.0 million in 2026.
• The last three Change in Taxes figures came in at -$683.0 million (Q1 2026), -$814.0 million (Q4 2025), and -$266.0 million (Q3 2025), per Business Quant data.